Corticosteroid-induced Kaposi’s sarcoma in a patient with systemic lupus erythematosus

ABSTRACT

We describe a 57-year old patient with SLE who developed Kaposi’s sarcoma after the corticosteroid treatment. Discontinuation of corticosteroids was followed by a complete remission of the disease and two attempts to reintroduce corticosteroids resulted in exacerbations of Kaposi’s sarcoma, which subsided again when the corticosteroid dosage was significantly reduced. The Kaposi’s sarcoma lesions and the patient’s peripheral blood were positive for HHV-8. The natural history of the disease indicates a direct relationship between corticosteroid-induced immunosuppression and Kaposi’s sarcoma.

Key words: Kaposi’s sarcoma; Corticosteroids; HHV-8

The characterization of Kaposi’s sarcoma associated herpes virus/human herpesvirus-8 (KSHV/HHV-8) as the causative agent for KS (4,5), strengthens the hypothesis that corticosteroid treatment may accelerate the progression or even induce the development of KS lesions, in patients who are already infected with the HHV-8 virus. The growth of KS seems to be controlled by host factors, and dysregulation of host immunity by autoimmune disease as well as CS-induced immunosuppression (where both the disease and the therapy interfere with the host immunity) may alter the natural history of the disease.

CASE REPORT

A 57-year-old woman, with a four-year history of systemic lupus erythematosus (SLE), developed autoimmune haemolytic anemia and was treated with methylprednisolone (32 mg/day). Anemia remitted, but three months later she noticed a brownish lesion (macular about 1cm in diameter) on her left thigh. Lesions gradually became numerous; histologic examination was compatible with Kaposi’s sarcoma (KS) and she was referred to our hospital.

She had several brownish-to-reddish nodules spread all over her body, extremities and face and a reddish nodule on the soft palate mucosa. Routine laboratory values and lymphocyte subpopulations were normal and she had a negative HIV-test, which remained negative for the whole 4-year follow-up period. Antibodies for HBV (Hepatitis B Virus), HCV (Hepatitis C Virus) and EBV (Ebstein-Barr Virus) were negative and IgG isotype antibodies to CMV (Cytomegalovirus) were positive (all assayed by ELISA). CT scan revealed borderline (about 1cm in diameter) enlargement of maxillary, mediastinal and retroperitoneal lymph nodes, of questionable clinical significance (location and size of these nodes remained unchanged during the 4-year follow-up). Endoscopic evaluation of the upper GI tract and a barium enema were normal. She received no treatment for KS, but corticosteroid (CS) treatment was stopped after a 45-days tapering period. Four months later skin lesions showed a marked reduction in size and number; oral lesion disappeared.

Six months later she had an exacerbation of SLE with malaise, arthralgias and Coombs-positive anemia. On fundoscopic examination she had bilateral juxtapapillary flame-shaped hemorrhages. Bone marrow aspirate revealed a severe depression of the erythroid precursors. Anemia did not respond to intravenous immunoglobulins (0.4 g/Kg/day for ten days) and 48 mg methylprednisolone per day were reintroduced. Reticulocyte/erythrocyte ratio, haematocrit and bone marrow aspirate gradually improved. Four months later, she developed a second relapse of multiple brownish lesions suggestive of KS.
Histologic examination confirmed again the diagnosis of KS. CS dosage was tapered to 4mg methylprednisolone daily (45-days tapering period) and no other treatment was given. Once again the lesions remitted completely.

The patient had two other KS relapses following increase of CS dosage to treat autoimmune haemolytic anemia crises. During her last KS relapse a biopsy was taken again, from a new lesion, revealing an early KS (Figure 1), positive to HHV-8 (Human Herpesvirus-8) by Polymerase Chain Reaction (4) (Figure 2).

KS lesions remitted again following CS dose tapering.

**DISCUSSION**

Remission of KS after CS-discontinuation has been reported previously in other patients. However, our patient is unique in expressing such an obvious relationship between KS development and CS treatment. Exacerbations and remissions of the Kaposi’s sarcoma seem to follow induction and withdrawal of CS treatment respectively, strongly suggesting an etiologic relationship. The appearance of the sarcoma in new sites could be explained by the fact that the virus is detected in the PBMCs and by the “viremic” infection of new endothelial cells.

The characterization of HHV-8 as the causative agent for KS provides possible explanations for two aspects of the KS development in patients with autoimmune disease treated with CS. First, it is possible that HHV-8 infects endothelial and spindle cells latently (6,7) immunosuppressive treatment can suppress host’s defense mechanisms and subsequently leads to KS development. More aggressive immunosuppressive treatment (e.g. in patients with autoimmune disease treated with CS) results in KS incidence, than less aggressive treatment (e.g. patients with autoimmune disease). Moreover, hydrocortisone can activate HHV-8 replication in vitro (8) and it is possible that this activation can also be induced in vivo by CS-treatment. Second, the dysregulation of host defense mechanisms and cytokine networks in patients with autoimmune disease, can further promote malignant transformation of HHV-8 infected cells (since several cytokines play important role in growth and proliferation of KS cells (9)).

The emergence of KS lesions in a patient with autoimmune disease receiving corticosteroids in the absence of other predisposing factors for the disease (e.g. HIV infection), should be regarded as treatment and/or disease related complication; discontinuation or modification of the immunosuppressive medication should be attempted, since it might result in KS remission. The use of antiviral drugs (10) may also be beneficial.

Acknowledgements

The authors wish to thank Professor H. Moutsopoulos for his helpful discussion and suggestions during the preparation of this manuscript.

**REFERENCES**